Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
(16 sites) United States
UC San Diego Moores Cancer Center, La Jolla, California Saddleback Memorial Medical Center, Laguna Hills, California University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California Georgetown University, Washington D.C., District of Columbia AdventHealth Cancer Institute, Orlando, Florida Winship Cancer Institute of Emory University, Atlanta, Georgia University of Illinois Cancer Center, Chicago, Illinois Kansas City VA Medical Center, Kansas City, Kansas Walter Reed National Military Medical Center, Bethesda, Maryland Christus Health - Christus St. Vincent Regional Medical Center, Santa Fe, New Mexico East Carolina University, Greenville, North Carolina Thomas Jefferson University, Philadelphia, Pennsylvania Renovatio Clinical - El Paso, El Paso, Texas Baylor College of Medicine, Houston, Texas Renovatio Clinical, The Woodlands, Texas Puerto Rico
Auxilio Mutuo Cancer Center, San Juan